NCT04400578View on ClinicalTrials.gov

TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2)

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 7, 2020

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Cervical Intraepithelial Neoplasia Grade 1Cervical Intraepithelial Neoplasia Grade 2
Interventions
DEVICE

Trichloroacetic acid 85% (TCA)

Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.

Trial Locations (1)

4010

Department of gynaecology, Ordensklinikum Linz Ges.m.b.H, Barmherzige Schwestern, Linz

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

Krankenhaus Barmherzige Schwestern Linz

OTHER

NCT04400578 - TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2) | Biotech Hunter | Biotech Hunter